XTX Topco Ltd Acquires New Holdings in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)

XTX Topco Ltd acquired a new stake in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 23,332 shares of the biotechnology company’s stock, valued at approximately $134,000.

Other large investors have also added to or reduced their stakes in the company. Hsbc Holdings PLC bought a new position in Aldeyra Therapeutics in the 4th quarter valued at approximately $52,000. Capital Advisors Wealth Management LLC bought a new position in Aldeyra Therapeutics in the 1st quarter valued at approximately $62,000. Wealth Enhancement Advisory Services LLC bought a new position in Aldeyra Therapeutics during the 1st quarter worth approximately $63,000. Balyasny Asset Management L.P. bought a new position in Aldeyra Therapeutics during the 4th quarter worth approximately $56,000. Finally, Regal Investment Advisors LLC bought a new position in Aldeyra Therapeutics during the 4th quarter worth approximately $66,000. Institutional investors own 59.71% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on ALDX. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a report on Monday, May 19th. Wall Street Zen upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 21st.

Insider Activity at Aldeyra Therapeutics

In other news, insider Stephen Machatha sold 22,073 shares of the firm’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $5.15, for a total transaction of $113,675.95. Following the completion of the sale, the insider owned 221,799 shares of the company’s stock, valued at $1,142,264.85. This trade represents a 9.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 9.60% of the stock is currently owned by company insiders.

Aldeyra Therapeutics Stock Performance

Aldeyra Therapeutics stock opened at $5.30 on Friday. Aldeyra Therapeutics, Inc. has a 52-week low of $1.14 and a 52-week high of $7.20. The firm has a 50 day moving average price of $4.35 and a two-hundred day moving average price of $4.25. The firm has a market cap of $317.47 million, a price-to-earnings ratio of -6.24 and a beta of 0.76.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.05. As a group, equities research analysts predict that Aldeyra Therapeutics, Inc. will post -0.92 EPS for the current fiscal year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.